Abraham Noah Oler
President at Allos Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Rajesh Shrotriya | M | 79 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 24 years |
| Luigi Lenaz | M | 83 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
| Bimal Shah | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
| Keith M. McGahan | M | - | 8 years | |
| William Pelham Barr | M | 73 |
Kirkland & Ellis LLP
 Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 15 years |
| Jeffrey R. Latts | M | 76 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 17 years |
| Mary Shoemaker | F | 63 | 4 years | |
| Rick Shrotri | M | - |
Digital Alpha Advisors LLC
 Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 7 years |
| James E. Shields | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 14 years |
| Harry Kraemer | M | 69 |
Kellogg School of Management
| 19 years |
| Jesus R Vega | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 3 years |
| Matthew Parris | M | - | 6 years | |
| Shiju Rajagopalan | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 2 years |
| Terry Whalen | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 3 years |
| Karl Meyer | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 3 years |
| Jeff Frazier | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 5 years |
| Olsen Edward | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 4 years |
| Dave Ward | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 4 years |
| Scott Puopolo | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 3 years |
| Andy Alcon | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | - |
| Michael A. Grabow | M | - | 11 years | |
| David L. Dixon | M | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 17 years |
| Bradley C. Reed | M | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 17 years |
| Cornelius Sheridan | M | - |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 4 years |
| Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 years |
| Vasa Babic | M | 57 |
Digital Alpha Advisors LLC
Digital Alpha Advisors LLC Investment ManagersFinance Digital Alpha Advisors LLC (Digital Alpha Advisors) is a private equity firm founded in 2017 by Rick Shrotri. The firm is headquartered in Henderson, Nevada. | 5 years |
| Daniel E. Wolf | M | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 15 years |
| Davis Stowell | M | 71 |
Kellogg School of Management
| 19 years |
| Rachel Masory | F | - |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | 15 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Riga | M | 48 | 10 years | |
| Joseph W. Turgeon | M | 66 | 9 years | |
| Ramesh Kumar | M | 68 | 21 years | |
| Michael Hoffman | M | 73 | 18 years | |
| Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 years |
| Kurt Gustafson | M | 55 | 9 years | |
| Brett Scott | M | 73 | - | |
| Jeffrey C. Hammes | M | 64 |
Kirkland & Ellis LLP
Kirkland & Ellis LLP Miscellaneous Commercial ServicesCommercial Services Kirkland & Ellis LLP provides legal services. It counsels clients in litigation, corporate and tax, intellectual property and restructuring matters. The firm offers intellectual property, antitrust and competition, international trade and national security, real estate and tax, benefits and estate planning services. The company was founded in 1909 and is headquartered in Chicago, IL. | - |
| David Stout | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 years |
| Iskandar Saleh | M | 68 |
University of Pennsylvania
| 1 years |
| R. Kenneth Bryant | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Raymond Cohen | M | 65 | 7 years | |
| David Clark | M | 56 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 years |
| Nazar Yasin | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Wing Kun Hui | M | 43 |
London School of Economics & Political Science
| 5 years |
| Paras P. Maniar | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Ee Ern Tan | M | 44 |
London School of Economics & Political Science
| 5 years |
| Nicholas Ng | M | - |
London School of Economics & Political Science
| 4 years |
| Shaia D. Hosseinzadeh | M | - |
London School of Economics & Political Science
| 4 years |
| Krishan K. Arora | M | 83 | 3 years | |
| Mei Qing Ren | F | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Leon Kuan | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Gabe Greenbaum | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Robert Fralin | M | - | - | |
| Dolatrai Vyas | M | 80 | 9 years | |
| Zain Al-Abidin ibni Muhriz | M | 41 |
London School of Economics & Political Science
| 5 years |
| Joseph C. Dwyer | M | - |
Northwestern University School of Law
| 3 years |
| Anton G. Gueth | M | 67 | 1 years | |
| Nathalie Tocci | M | 47 |
London School of Economics & Political Science
| 5 years |
| Ben Gulliver | M | - |
London School of Economics & Political Science
| 4 years |
| Saul Goldstein | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Elizabeth Stevens | F | 45 |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Irene Rika Shimada | F | - |
London School of Economics & Political Science
| 4 years |
| Peter M. Lamb | M | - |
University of Pennsylvania
| 3 years |
| Erik Oliver | M | - |
University of Pennsylvania
| 3 years |
| Raul Ramirez | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Alex Lloyd | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Gilles Gagnon | M | 70 | - | |
| Jonathan Leff | M | 55 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 7 years |
| David M. Hollond | M | - |
University of Pennsylvania
| 2 years |
| Bernice Welles | M | 71 | - | |
| James S. Riepe | M | - |
University of Pennsylvania
| 4 years |
| Phil Bronner | M | 53 |
The Wharton School of the University of Pennsylvania
| 3 years |
| George Ng | M | 49 | 3 years | |
| Erik Mayo | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 4 years |
| Sandeep Murthy | M | 47 |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 4 years |
| Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
| Ricardo J. Gonzalez | M | 53 | 6 years | |
| Steve Carlson | M | - |
Kellogg School of Management
The Wharton School of the University of Pennsylvania
| 6 years |
| Sebastian Arango | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 years |
| Atif U. Gilani | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 4 years |
| Leonard M. Greenstein | M | 48 | 7 years | |
| Maja M. Gross | F | - |
The Wharton School of the University of Pennsylvania
| 6 years |
| Aydin Senkut | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 years |
| Fernando Goni | M | 50 |
London School of Economics & Political Science
| 5 years |
| E. Premkumar Reddy | M | 80 | 22 years | |
| Joel Lloyd Gantcher | M | - |
University of Pennsylvania
| 2 years |
| J. Kim | M | 55 |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 4 years |
| Richard Thompson | M | - |
The Wharton School of the University of Pennsylvania
University of Pennsylvania
| 2 years |
| Juan Felipe Muñoz | M | - |
Kellogg School of Management
| 2 years |
| Carlton Barclay | M | - |
Kellogg School of Management
| 2 years |
| Amita Shetty | F | 47 |
Kellogg School of Management
| 2 years |
| William C. Reed | M | - |
The Wharton School of the University of Pennsylvania
| 2 years |
| Gabriel Mizrahi | M | - |
Kellogg School of Management
| 2 years |
| John Chesnut | M | 51 |
Kellogg School of Management
| 2 years |
| Tucker Morrison | M | - |
Kellogg School of Management
| - |
| Takeshi Saito | M | 52 |
Kellogg School of Management
| 2 years |
| Túlio Toledo Abi-Saber | M | 47 |
Kellogg School of Management
| 2 years |
| Adrian Paulino Ramos | M | 45 |
Kellogg School of Management
| 2 years |
| Sunil K. Bilolikar | M | 62 |
The Wharton School of the University of Pennsylvania
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 91 | 91.00% |
| United Kingdom | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Abraham Noah Oler
- Personal Network
